Background/aims: We investigated the efficacy of entecavir (ETV) monotherapy in 54 naïve patients and 27 lamivudine (LMV) and/or adefovir (ADV) experienced patients.
Methods: Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0.5mg daily. The viruses of patients were sequenced before ETV therapy and after every three months of ETV therapy.
Results: Eight LAM-experienced and ADV-experienced patients emerged mutations in the ETV treatment. In one of these experienced patients, the ETV-resistant mutations were detected during ETV treatment, with the virological and the biochemical breakthrough. Two LAM-experienced and ADV-naïve patients were detected mutation during 1-2 years ETV therapy. All three LAM-naïve and ADV-experienced patients were detected mutations in the ETV treatment. Five in fifty for LAM-naïve and ADV-naïve patients showed mutations in the ETV monotherapy.
Conclusions: ETV has a high genetic barrier to resistance and the efficacy in LAM-experienced and/or ADV-experienced patients were much lower than in naïve patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinre.2016.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
Aliment Pharmacol Ther
December 2018
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
Background: Long term renal safety of antiviral agents against hepatitis B virus (HBV) has been debated.
Aim: To compare longitudinal trends of renal function among HBV mono-infected patients receiving entecavir (ETV), tenofovir disoproxil fumarate (TDF), and adefovir (ADV) in comparison to untreated subjects.
Methods: A retrospective cohort consisting of 815 patients with chronic HBV infection was constructed.
Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B.
Clin Res Hepatol Gastroenterol
November 2016
The Second Hospital of Nanjing affiliated to Medical School of Southeast University, 210003 Nanjing, China. Electronic address:
Background/aims: We investigated the efficacy of entecavir (ETV) monotherapy in 54 naïve patients and 27 lamivudine (LMV) and/or adefovir (ADV) experienced patients.
Methods: Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0.5mg daily.
A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients.
Sci Rep
July 2016
Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Entecavir (ETV) is a potent viral replication inhibitor for chronic hepatitis B (CHB) patients. To investigate the efficacy of ETV in Chinese nucleos(t)ide(NA)-experienced CHB patients. Among 89 CHB patients with ETV monotherapy for ≥6 months, 33/89 (37%) or 56/89 (73%) were NA-naïve or NA-experienced.
View Article and Find Full Text PDFSafety and efficacy of entecavir in adefovir-experienced patients.
J Gastroenterol Hepatol
January 2015
School of Medicine, University of California San Diego, San Jose, California, USA.
Background And Aim: Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B. Few studies have evaluated the efficacy of entecavir (ETV) in ADV-experienced patients. Our aim is to assess treatment effectiveness of ETV in ADV-experienced patients.
View Article and Find Full Text PDFEfficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B.
Antivir Ther
August 2015
Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey.
Background: Tenofovir (TDF) has similar antiviral efficacy in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients. Data on TDF use in patients with adefovir (ADV) resistance is inconsistent. The aim of our study was to assess antiviral efficacy of TDF against nucleoside analogue-naive (NN) and ADV-resistant (ADV-R) CHB and suboptimal responders to ADV (ADV-S).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!